5 Top Value Stocks with High Earnings Yields Before Important Economic Reports
Market Trends: Markets closed slightly lower as investors reassess AI stock valuations, leading to a shift from tech to value stocks amid upcoming economic data releases, including the November jobs report and inflation updates.
Value Investing Focus: The article emphasizes the importance of value investing, which prioritizes a company's intrinsic value and earnings potential, especially during volatile market conditions where hype may lead to overvaluation.
Earnings Yield Metric: Earnings yield is highlighted as a key metric for identifying undervalued stocks, with a focus on companies that have strong earnings relative to their market price, and comparisons to fixed-income securities like Treasury yields.
Highlighted Stocks: Five stocks with strong growth potential and high earnings yield are mentioned, including CorMedix, Centerra Gold, Commercial Metals, CommScope, and Seanergy Maritime, all of which have favorable Zacks rankings and growth estimates.
Trade with 70% Backtested Accuracy
Analyst Views on CRMD
About CRMD
About the author

CorMedix to Present Corporate Overview at 44th J.P. Morgan Healthcare Conference
- Conference Presentation: CorMedix Therapeutics will present a corporate overview at the 44th J.P. Morgan Healthcare Conference on January 12, 2026, at 4:30 PM PST, aiming to enhance investor awareness of its product portfolio.
- Product Line Expansion: The company is commercializing DefenCath® for preventing catheter-related bloodstream infections in adult patients undergoing dialysis, while also promoting a diverse range of anti-infective products, showcasing its strategic diversification in the biopharmaceutical sector.
- Clinical Research Progress: CorMedix is conducting clinical studies for DefenCath in Total Parenteral Nutrition and pediatric dialysis populations, which are expected to provide crucial data support for future product development.
- Future Outlook: Topline results from the Phase III study of REZZAYO are anticipated in Q2 2026, which will provide a new impetus for the company's competitiveness in the antifungal treatment market.

CorMedix and GM See Significant Options Trading Volume Surge
- CorMedix Options Trading: CorMedix Inc experienced options trading volume of 12,556 contracts, equivalent to approximately 1.3 million shares, representing about 44.3% of its average daily trading volume over the past month, indicating heightened market interest in its future performance.
- High Demand Options: Within CorMedix, the $9 strike call option expiring on June 18, 2026, saw 1,831 contracts traded, representing around 183,100 underlying shares, suggesting investor expectations for a price increase.
- GM Options Trading: General Motors recorded options trading volume of 38,071 contracts, translating to approximately 3.8 million shares, which is about 44% of its average daily trading volume over the past month, reflecting active market interest in its stock.
- Bullish Options Activity: For GM, the $85 strike call option expiring on January 16, 2026, had a trading volume of 5,577 contracts, representing approximately 557,700 shares, indicating strong investor confidence in future price appreciation.






